UCMYM802 not checked

UTC Therapeutics Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“1×10\^8\~2×10\^9 cells will be infused intravenously for 4 times.”In the company’s words, NCT06256055 on ClinicalTrials.gov
Tested for
Malignant Mesothelioma, Colorectal Cancer, Bile Duct Cancer, Rectal Cancer, Ovary Cancer, Pancreatic Cancer, Breast Cancer Female
Main trialPhase 1
“This is a first-in-human, single-arm, open-label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, immunogenicity and preliminary efficacy of UCMYM802 (Circular mRNA encoding Anti-Mesothelin CAR-T) injection in patients with Mesothelin-positive advanced malignant solid tumors.”In the company’s words, NCT06256055 on ClinicalTrials.gov

Other drugs for Malignant Mesothelioma

All 29 drugs for Malignant Mesothelioma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Unknown Mar 2025 Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow UCMYM802

Following is part of Solo: you see every change to UCMYM802 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in